Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis Theme

1-677-124-44227

184 MAIN COLLINS STREET WEST VICTORIA 8007

FOLLOW US ON INSTAGRAM
Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies

The No.1 Research Site For Therapeutic Peptides

Top

CJC-1295 2mg

INTRODUCING

CJC-1295 2mg

CJC-1295 is a synthetic peptide and a long-acting analogue of growth hormone-releasing hormone (GHRH), which stimulates the production and release of growth hormone (GH) from the pituitary gland. The peptide was initially developed by ConjuChem Biotechnologies, and its full name is CJC-1295 without DAC (Drug Affinity Complex), as it does not contain a DAC component. The peptide is a modification of GHRH(1-29), with improved pharmacokinetics and biological activity.

CJC-1295 has attracted interest in the scientific and medical communities due to its potential benefits in various areas, including:

  1. Aging: As a potent growth hormone secretagogue, CJC-1295 has been studied for its potential to counteract age-related declines in growth hormone levels. Research has shown that it can improve growth hormone secretion, which in turn may lead to beneficial effects on body composition, muscle mass, bone density, and overall vitality.
  2. Muscle growth and recovery: Studies have shown that CJC-1295 can stimulate the release of growth hormone, which is known to promote muscle growth and repair. This has led to interest in the potential use of CJC-1295 for athletes and bodybuilders, as well as those recovering from injury or surgery.
  3. Fat loss: Growth hormone is known to play a role in regulating body fat, and research on CJC-1295 has suggested that it may help to promote fat loss by increasing growth hormone levels.
  4. Improved sleep: Growth hormone is released during deep sleep, and research has shown that CJC-1295 may help to improve sleep quality, which could lead to increased growth hormone release and improved overall health.

Research on CJC-1295 is ongoing, and there is still much to learn about its safety, efficacy, and potential applications. Some of the current research directions include:

  1. Long-term safety and efficacy: As CJC-1295 is a relatively new compound, long-term studies are needed to establish its safety and efficacy in various populations and for different indications.
  2. Combination therapies: Researchers are investigating the potential benefits of combining CJC-1295 with other peptides or compounds to enhance its effects or to target specific outcomes, such as muscle growth, fat loss, or improved sleep.
  3. Specific medical applications: Studies are ongoing to explore the potential use of CJC-1295 in the treatment or management of various medical conditions, such as growth hormone deficiency, sarcopenia, osteoporosis, or obesity.
  4. Optimization of dosing and administration: Research is being conducted to determine the optimal dosing and administration protocols for CJC-1295 to maximize its therapeutic effects while minimizing potential side effects.

While the results of early research on CJC-1295 are promising, it is important to note that the peptide is not currently approved for use as a medication, and its use in sports is prohibited by the World Anti-Doping Agency (WADA). As research continues, more information will be available about the potential benefits, risks, and applications of CJC-1295 in various fields.



Peptides are the future of medicine. They are potent, tissue specific and effective at treating a variety of conditions with little to no side effects.

Dean Henry
Function Medicine Coach and Health Optimiser

Peptides are the next frontier in biohacking and performance enhancement. They can boost muscle growth, accelerate fat loss, improve sleep, increase energy and focus, and promote overall health and longevity.

Ben Greenfield
Biohacker and Health Expert

Peptides are tiny chains of amino acids that have powerful effects on the brain and body. They can improve memory, focus, and mood, and have anti-anxiety and anti-depressant effects.

Dr. Andrew Huberman, PhD
Professor of Neurobiology at Stanford University